Page 138 - 《中国药房》2023年15期
P. 138

and dosing considerations for biliary tract infections based   [J]. Pharmacotherapy,2006,26(9):1320-1332.
               on  site-specific  pharmacodynamic  target  attainment[J].   [33]  ABDUL-AZIZ  M  H,BRADY  K,COTTA  M  O,et  al.
               Antimicrob Agents Chemother,2011,55(12):5609-5615.  Therapeutic  drug  monitoring  of  antibiotics:defining  the
          [19]  NAGASHIMA S,KOZAWA O,OTSUKA T,et al. Phar‐         therapeutic range[J]. Ther Drug Monit,2022,44(1):19-31.
               macokinetics of a parenteral carbapenem,biapenem,in pa‐  [34]  WILLIAMS P,COTTA M O,ROBERTS J A. Pharmaco‐
               tients with end-stage renal disease and influence of haemo‐  kinetics/pharmacodynamics  of  β -lactams  and  therapeutic
               dialysis[J]. J Antimicrob Chemother,2000,46(5):839-842.  drug monitoring:from theory to practical issues in the in‐
          [20]  AKASHITA  G,HOSAKA  Y,NODA  T,et  al.  PK/PD       tensive care unit[J]. Semin Respir Crit Care Med,2019,40
               analysis  of  biapenem  in  patients  undergoing  continuous   (4):476-487.
               hemodiafiltration[J]. J Pharm Health Care Sci,2015,1:31.  [35]  ABDUL-AZIZ M H,LIPMAN J,AKOVA M,et al. Is pro‐
          [21]  肖仲祥,陈朴,邵传锋,等. 比阿培南在连续性肾替代治                         longed  infusion  of  piperacillin/tazobactam  and  merope‐
               疗患者中的药动学研究[J]. 中国现代应用药学,2018,35                     nem  in  critically  ill  patients  associated  with  improved
              (2):256-260.                                         pharmacokinetic/pharmacodynamic  and  patient  outcomes?
          [22]  陈亚芳,杭永付,薛领,等. 重症患者比阿培南群体药动                         An  observation  from  the  Defining  Antibiotic  Levels  in
               学研究[J]. 中国药学杂志,2016,51(6):478-482.                  Intensive care unit patients (DALI) cohort[J]. J Antimicrob
          [23]  朱建国,杭永付,顾继红,等 . 蒙特卡洛模拟评价 ICU 鲍                     Chemother,2016,71(1):196-207.
               曼不动杆菌感染中比阿培南的给药方案[J]. 中国药学杂                    [36]  IKAWA K,MORIKAWA N,IKEDA K,et al. Pharmacoki‐
               志,2017,52(24):2218-2222.                            netic  modeling  and  dosage  adaptation  of  biapenem  in
          [24]  蔡艳,张抗怀,王娜,等. 应用蒙特卡洛模拟法观察比阿                         Japanese patients during continuous venovenous hemodia‐
               培南在不同给药方案下的目标获取概率[J]. 药学服务与                         filtration[J]. J Infect Chemother,2008,14(1):35-39.
               研究,2015,15(4):257-260.                         [37]  GRIFFITH D C,MORGAN E E,DUDLEY M N,et al. A
          [25]  DONG  J,CHEN  Y  C,XIONG  W,et  al.  Efficacy  and   phase 1 study of the safety,tolerability,and pharmacoki‐
               safety  of  biapenem  against  lower  respiratory  tract  infec‐  netics  of  biapenem  in  healthy  adult  subjects[J].  Antimi‐
               tions in elderly Chinese patients and optimal dosing regi‐  crob Agents Chemother,2023,65(5):e02612-e02620.
               men based on pharmacokinetic/pharmacodynamic analysis  [38]  DHAESE S,VAN VOOREN S,BOELENS J,et al. Thera‐
               [J]. J Chemother,2016,28(5):403-410.                peutic drug monitoring of β-lactam antibiotics in the ICU[J].
          [26]  IKAWA  K, MORIKAWA  N, IKEDA  K, et  al.           Expert Rev Anti Infect Ther,2020,18(11):1155-1164.
               Pharmacokinetic-pharmacodynamic   target   attainment   [39]  IKEDA K,IKAWA K,IKEDA A,et al. A simple and rapid
               analysis  of  biapenem  in  adult  patients:a  dosing  strategy  determination  of  biapenem  in  plasma  by  high-
               [J]. Chemotherapy,2008,54(5):386-394.               performance  liquid  chromatography[J].  J  Chromatogr  B
          [27]  IKAWA K,MORIKAWA N,IKEDA K,et al. Population       Analyt Technol Biomed Life Sci,2006,844(1):148-152.
               pharmacokinetics and pharmacodynamics of biapenem in   [40]  钱亚芳,杨旭萍,蒋艳,等 . LC-MS/MS 法测定人血浆中
               paediatric  patients[J].  J  Clin  Pharm Ther,2008,33(2):  比阿培南浓度[J]. 中南药学,2023,21(2):432-436.
               203-210.                                       [41]  李博涵,彭秘,封传华,等 . HPLC 法测定人血清中游离
          [28]  汪继涛,包健安,顾继红,等. 重症监护患者肠杆菌科细                         比阿培南浓度及其在重症感染中的临床应用[J]. 药品评
               菌感染比阿培南给药方案的优化[J]. 中国医院药学杂                          价,2022,19(14):861-864.
               志,2018,38(5):506-509.                          [42]  MOUTON J W,MULLER A E,CANTON R,et al. MIC-
          [29]  吴登科,薛领,张险峰,等 . ICU 铜绿假单胞菌感染中比                      based  dose  adjustment:facts  and  fables[J].  J Antimicrob
               阿培南给药方案的优化[J]. 中国抗生素杂志,2017,42                      Chemother,2018,73(3):564-568.
              (11):998-1002.                                  [43]  HOBAN  D  J,JONES  R  N,YAMANE  N,et  al.  In  vitro
          [30]  IKAWA K,MORIKAWA N,IKEDA K,et al. Pharmacody‐      activity  of  three  carbapenem  antibiotics.  Comparative
               namic  evaluation  of  biapenem  in  peritoneal  fluid  using   studies with biapenem (L-627),imipenem,and meropenem
               population  pharmacokinetic  modelling  and  Monte  Carlo   against  aerobic  pathogens  isolated  worldwide[J].  Diagn
               simulation[J].  Int  J  Antimicrob  Agents,2008,32(4):  Microbiol Infect Dis,1993,17(4):299-305.
               339-343.                                       [44]  陈文倩,刘晓,李朋梅,等. 群体药物动力学在治疗药物
          [31]  中国医药教育协会感染疾病专业委员会. 抗菌药物药代                          监测中的应用[J]. 中国医院用药评价与分析,2012,12
               动力学/药效学理论临床应用专家共识[J]. 中华结核和                        (9):855-859.
               呼吸杂志,2018,41(6):409-446.                       [45]  陈文倩,杭永付,张丹,等. f%T>MIC计算模型的建立及重
          [32]  LODISE T P,LOMAESTRO B M,DRUSANO G L,et al.        症患者碳青霉烯类抗菌药物个体化用药方案的优化[J].
               Application  of  antimicrobial  pharmacodynamic  concepts   中国药学杂志,2018,53(15):1313-1317.
               into clinical practice:focus on beta-lactam antibiotics:in‐  (收稿日期:2022-12-23  修回日期:2023-07-13)
               sights from the Society of Infectious Diseases Pharmacists                         (编辑:胡晓霖)



          · 1920 ·    China Pharmacy  2023 Vol. 34  No. 15                            中国药房  2023年第34卷第15期
   133   134   135   136   137   138   139   140